Intensive Glycemic Control in Type 2 Diabetes Mellitus -- A Balancing Act of Latent Benefit and Avoidable Harm: A Teachable Moment

JAMA Intern Med. 2016 Mar;176(3):300-1. doi: 10.1001/jamainternmed.2015.8320.

Authors

Rene Rodriguez-Gutierrez¹, Kasia J Lipska², Rozalina G McCoy³

Affiliations

¹ Knowledge and Evaluation Research Unit, Division of Endocrinology, Diabetes, Metabolism and Nutrition, Department of Medicine, Mayo Clinic, Rochester, Minnesota2Endocrinology Division, Department of Internal Medicine, University Hospital "Dr Jose E. Gonza.
² Section of Endocrinology, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut.
³ Division of Primary Care Internal Medicine, Department of Medicine, Mayo Clinic, Rochester, Minnesota5Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota.

No abstract available

Publication types

Case Reports
Research Support, N.I.H., Extramural

MeSH terms

Anxiety / etiology
Anxiety / prevention & control
Biomarkers / blood
Blood Glucose / metabolism*
Comorbidity
Diabetes Mellitus, Type 2 / blood*
Diabetes Mellitus, Type 2 / drug therapy*
Diabetes Mellitus, Type 2 / psychology
Glycated Hemoglobin / metabolism*
Humans
Hyperglycemia / prevention & control
Hypoglycemia / blood
Hypoglycemia / chemically induced*
Hypoglycemic Agents / administration & dosage
Hypoglycemic Agents / adverse effects*
Insulin / administration & dosage
Insulin / adverse effects*
Male
Middle Aged
Patient Care Team
Patient Participation*

Substances

Biomarkers
Blood Glucose
Glycated Hemoglobin A
Hypoglycemic Agents
Insulin
hemoglobin A1c protein, human

Grants and funding